par Leleu, Xavier;Fouquet, Guillemette;Richez, Valentine;Guidez, Stéphanie;Duhamel, Alain;Machuron, François;Karlin, Lionel;Kolb, Brigitte;Tiab, Mourad;Araujo, Carla;Meuleman, Nathalie ;Malfuson, Jean Valère;Bourquard, Pascal;Lenain, Pascal;Roussel, Murielle;Jaccard, Arnaud;Pétillon, Marie-Odile;Belhadj-Merzoug, Karim;Lepeu, Gérard;Chrétien, Marie-Lorraine;Fontan, Jean;Rodon, Philippe;Schmitt, Anna;Offner, Fritz;Voillat, Laurent;Cereja, Sophie;Kuhnowski, Frédérique;Rigaudeau, Sophie;Decaux, Olivier;Humbrecht-Kraut, Catherine;Frayfer, Jamile;Fitoussi, Olivier;Roos-Weil, Damien;Eisenmann, Jean Claude;Dorvaux, Véronique;Voog, Eric G;Attal, Michel;Moreau, Philippe;Avet-Loiseau, Herve;Hulin, Cyrille;Facon, Thierry
Référence Clinical cancer research, 25, 14, page (4224-4230)
Publication Publié, 2019-07-01
Référence Clinical cancer research, 25, 14, page (4224-4230)
Publication Publié, 2019-07-01
Article révisé par les pairs
Résumé : | Carfilzomib is a novel generation proteasome inhibitor. The Carmysap trial demonstrated that twice-weekly KMP (carfilzomib, melphalan, prednisone) might challenge the MPV (melphalan, prednisone, bortezomib) standard. We sought to study KMP weekly, allowing to increase carfilzomib's dose with maintained efficacy and improved safety profile. |